Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Oric Pharmaceuticals, Inc. (ORIC : NSDQ)
 
 • Company Description   
ORIC Pharmaceuticals Inc. is a clinical stage oncology company. It is focused on developing treatments which address mechanisms of therapeutic resistance. The company's product candidate consists of ORIC-101 and ORIC-533 which are in clinical stage. ORIC Pharmaceuticals Inc. is based in San Francisco, United States.

Number of Employees: 78

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.50 Daily Weekly Monthly
20 Day Moving Average: 506,436 shares
Shares Outstanding: 39.48 (millions)
Market Capitalization: $138.17 (millions)
Beta: 2.40
52 Week High: $26.50
52 Week Low: $2.62
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -9.79% -1.16%
12 Week -57.93% -54.35%
Year To Date -76.19% -71.69%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
240 E. GRAND AVE. 2ND FLOOR
-
SOUTH SAN FRANCISCO,CA 94080
USA
ph: 650-388-5600
fax: -
investors@oricpharma.com http://www.oricpharma.com
 
 • General Corporate Information   
Officers
Jacob M. Chacko - Chief Executive Officer and President
Richard Heyman - Chairman
Dominic Piscitelli - Chief Financial Officer
Mardi Dier - Director
Steven Hoerter - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 68622P109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/09/22
Share - Related Items
Shares Outstanding: 39.48
Most Recent Split Date: (:1)
Beta: 2.40
Market Capitalization: $138.17 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.60 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.44 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/09/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.55
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -31.11%
vs. Previous Quarter: -1.72%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -31.74
12/31/21 - -28.65
09/30/21 - -30.19
ROA
03/31/22 - -29.53
12/31/21 - -27.03
09/30/21 - -28.90
Current Ratio
03/31/22 - 20.23
12/31/21 - 15.88
09/30/21 - 24.60
Quick Ratio
03/31/22 - 20.23
12/31/21 - 15.87
09/30/21 - 24.60
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 6.41
12/31/21 - 6.93
09/30/21 - 7.41
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©